Amydramine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amydramine

Amydramine is a combination product formulated as an oral solution or syrup, classified pharmacologically as a compound anti-allergic, antitussive, and expectorant preparation. Its primary role is to provide effective, simultaneous relief from the key symptoms associated with the common cold, respiratory discomfort, and minor allergic conditions.

Quick Facts Description
Active Ingredients Diphenhydramine HCl, Ammonium Chloride, Levomenthol, Sodium Citrate
Form Oral solution / Syrup
Pharmacological Class Compound anti-allergic, antitussive, expectorant
Common Use Symptomatic relief of cold and allergy discomfort
Origin Synthetic/Derived (multi-component)

Identity and Pharmaceutical Classification

Amydramine is a multi-component pharmaceutical entity designed for comprehensive symptomatic support of the upper respiratory tract. The core ingredient, Diphenhydramine Hydrochloride, functions as a first-generation antihistamine, blocking the effects of histamine in the body. This action helps to ease discomfort associated with allergic symptoms like sneezing and a runny nose. The combined action ensures the preparation addresses multiple facets of respiratory discomfort, distinguishing it from single-agent antihistamines. This combination approach is designed for addressing cough and cold symptoms simultaneously.

Active Components and Composition Type

The preparation's efficacy stems from four distinct active ingredients: Diphenhydramine Hydrochloride, Ammonium Chloride, Levomenthol, and Sodium Citrate. These components are primarily synthetic or derived from known chemical entities, blended into an aqueous syrup base that often features distinct flavoring to improve patient compliance. The composition is designed to promote multiple physiological effects; for example, Ammonium Chloride is utilized for its recognized expectorant property by irritating the bronchial mucosa. This specific component contributes to the thinning of mucus in the airways, assisting the body in phlegm clearance.

General Purpose and High-Level Action

The overall purpose of Amydramine is to deliver generalized symptomatic support by mitigating congestion, allergic response, and cough-related irritation simultaneously. This is achieved through three integrated actions: the antihistamine action controls symptoms like sneezing and rhinorrhea, the expectorant action assists in the clearance of phlegm from the airways, and the Levomenthol component provides a distinct soothing effect on the irritated throat. This structural combination is recognized as beneficial for addressing the multi-symptom presentation typical of the common cold.

Regulatory References

  1. National Institutes of Health, DailyMed

What side effects are possible with Amydramine?

Possible Side Effects and Safety Information

The name Amydramine appears in some regulatory contexts as a brand name for products containing the active ingredient diphenhydramine. The safety profile described here is based on the official governmental regulatory documents for diphenhydramine, a well-established first-generation antihistamine.

Key Adverse Reactions

The most frequent adverse reaction is Central Nervous System (CNS) Depression, commonly leading to drowsiness and sedation. Other common side effects, classified under Anticholinergic effects, include dry mouth, dry nose, dry throat, difficulty with urination, and blurred vision.

Frequency Classification (Common) System-Organ Class (SOC)
Drowsiness, Sedation Nervous System Disorders
Dry Mouth, Blurred Vision Anticholinergic Effects
Dizziness, Coordination problems Nervous System Disorders

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions, though less common, are associated with the use of diphenhydramine, particularly at higher-than-recommended doses. These reactions are typically related to marked CNS stimulation or depression. Regulatory warnings from bodies like the FDA emphasize that high doses can lead to seizures, coma, serious heart problems, or death.

  • Pediatric Safety: In children, the drug may rarely cause paradoxical excitation (restlessness, nervousness) before possible sedation. The use of diphenhydramine-containing cough and cold products is cautioned by health authorities, particularly in children under two years of age.
  • Geriatric Safety: Older adults are considered a high-risk population for this class of medicine due to an increased risk of confusion, falls, and pronounced anticholinergic effects.

Safety Restrictions and Limitations

  • Use of this medication is not recommended for patients with specific pre-existing conditions that can be worsened by its anticholinergic effects, such as narrow-angle glaucoma, a history of difficult or painful urination, or an enlarged prostate gland.
  • Patients are formally cautioned against the concurrent use of alcohol or other CNS depressants due to the risk of additive effects, which can increase sedation and impairment.

This information is strictly derived from official government-mandated drug labels and public safety communications, and serves as the regulatory framework for understanding the medicine's risk profile.

Overdose and Emergency Response

The official regulatory information states that overdose of Amydramine may result in a wide spectrum of toxicity, primarily driven by its antihistamine component. Documented overdose presentations involve significant Central Nervous System (CNS) changes, which can range from marked drowsiness and confusion to severe excitation, including agitation, hallucinations, delirium, and even seizures. Anticholinergic signs such as dry mouth, enlarged pupils (mydriasis), and blurred vision are also documented.

Life-threatening outcomes include major cardiac arrhythmias, profound hypotension, respiratory depression, coma, and death. Additionally, over-exposure to the Ammonium Chloride component can lead to a serious degree of metabolic acidosis.

Due to these severe risks, regulators mandate that any suspected overdose requires immediate medical attention or contacting poison control services. Urgent help is specifically required if the person is hallucinating, cannot be awakened, has a seizure, or has trouble breathing. Management is symptomatic and supportive, and no specific antidote is known. Hospital monitoring, including an Electrocardiogram (ECG), is often required for cardiac and metabolic stability. Population-specific notes indicate that children may exhibit paradoxical excitation.

Therapeutic Uses of Amydramine

Main Uses of Amydramine

Amydramine is a pharmaceutical formulation primarily used to manage symptoms associated with various respiratory conditions and allergic reactions. Its main applications include the relief of coughs and the mitigation of upper respiratory symptoms.

Cough Suppression

The medication is frequently utilized to alleviate productive and non-productive coughs. It works by addressing the underlying irritation in the respiratory tract, helping to reduce the frequency and intensity of coughing fits. This is particularly applicable in cases of coughs associated with the common cold or inhaled irritants.

Relief of Allergy Symptoms

As a treatment for allergic manifestations, Amydramine helps manage symptoms triggered by environmental allergens. These include:

  • Sneezing: Reducing the reflexive response to nasal irritants.
  • Rhinorrhea: Managing a runny nose caused by seasonal or perennial allergies.
  • Itchy and Watery Eyes: Alleviating ocular discomfort associated with hay fever.
  • Nasal Congestion: Assisting in the reduction of swelling in the nasal passages to improve airflow.

Upper Respiratory Congestion

Beyond specific allergic triggers, the medication is used to provide symptomatic relief from general upper respiratory congestion. By thinning or loosening mucus and reducing inflammation in the airways, it facilitates easier breathing for individuals experiencing discomfort from congestion due to minor infections or environmental factors.

Benefits of Treatment

The primary benefit of Amydramine is the improvement of daily comfort for patients suffering from persistent respiratory symptoms. By targeting multiple symptoms simultaneously—such as coughing and congestion—it provides a comprehensive approach to symptom management. This can lead to better rest and an improved ability to perform daily activities without the interruption of continuous coughing or nasal irritation.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory profile for Amydramine, a compound anti-allergic, antitussive, and expectorant preparation, establishes strict boundaries for its use based on population status and pre-existing health conditions.

Eligibility Scope

Classification Population or Condition
Contraindicated Nursing Mothers (Breastfeeding)
Contraindicated Neonates or Premature Infants
Contraindicated Children under 6 years of age (in many cough/cold formulations)
Contraindicated Patients who have taken MAO Inhibitors in the last 14 days
Contraindicated Known Hypersensitivity to any component

Condition-Specific Contraindications and Cautions:

Use is contraindicated in patients with a persistent, chronic cough or a cough with excessive secretions (phlegm). Regulatory documents require caution for patients with narrow-angle glaucoma, symptomatic prostatic hypertrophy (or urinary retention), severe hepatic impairment, renal impairment, or lower respiratory diseases like bronchial asthma. Use during pregnancy is generally not recommended and is restricted to situations where the need is clearly established. Older adults (ge 60 or ge 65 years) should use the medicine with caution.

What should I know about interactions with other medicines?

Amydramine Interactions with other medicines and products

The officially documented interaction profile for Amydramine, a multi-component product, is based on the properties of its active ingredients, primarily Diphenhydramine HCl and Ammonium Chloride. All interaction statements reflect information found in authoritative government regulatory documents.

Formal Contraindicated Combinations

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs is contraindicated. This combination is documented to prolong and intensify the anticholinergic effects of the antihistamine component. A period of at least 14 days must pass after discontinuing MAOI therapy before this product can be administered.

Documented Pharmacodynamic Interactions

Interactions involving an additive effect on the body's systems:

Interacting Substance Official Interaction Description
Alcohol Concomitant use has an additive effect resulting in increased central nervous system (CNS) depression.
CNS Depressants Additive effects occur with sedatives, tranquilizers, hypnotics, and similar drugs, leading to increased CNS depression.
Other Anticholinergics The potential exists for intensified anticholinergic (drying) effects.

Exposure-Altering Interactions

The Ammonium Chloride component is officially documented to influence the renal clearance of certain medicines:

  • Amphetamines and related CNS Stimulants: Ammonium Chloride decreases the blood levels of these substances by increasing their renal clearance.
  • Pseudoephedrine: The effects of Pseudoephedrine are decreased as its urinary excretion is increased by the acidifying action.

Population-Specific Considerations

Regulatory documents note that interaction risks are heightened in elderly patients due to increased likelihood of sedation and dizziness. Furthermore, the Ammonium Chloride component is contraindicated in patients with severe hepatic or renal impairment due to associated risks.

Mechanism of Action

Amydramine's mechanism of action involves multiple components acting on distinct biological pathways, primarily focusing on histaminergic signaling and respiratory tract fluid dynamics.

Antagonism of Histamine H1 Receptors

Diphenhydramine readily crosses the blood-brain barrier and functions as an inverse agonist at both peripheral and central histamine H1 receptors. This binding interaction alters downstream signaling, leading to the suppression of pathways associated with inflammation and neural excitation. This action decreases excitability within the central nervous system.


Modulation of Secretion Pathways

Ammonium Chloride exerts an irritant effect on bronchial mucosa, initiating signaling sequences that lead to an increase in respiratory tract fluid volume. Simultaneously, Sodium Citrate acts as a mucolytic to modify early molecular steps. The combined molecular activity changes the rheological properties (viscosity) and volume of the fluid within the respiratory tract.


Central Reflex Inhibition

Diphenhydramine also targets the medullary cough center in the brain. By engaging mechanisms of neural signal suppression at this site, the transmission of afferent signals is diminished, resulting in decreased central reflex activity.

Dosage and Administration Information

Instruction Map: How to use Amydramine — Administration Guidelines

This map details the administration instructions for Amydramine oral solution, providing the standard framework for combination anti-allergic and antitussive products.


Administration Scope

Category Standard Instruction
Route of administration Oral (by mouth), administered as a liquid solution or syrup.
Dosing schedule Standard Adult Dose (12+ years): 10 mL every 4 to 6 hours. Maximum Daily Dose: Total intake volume must not exceed 60 mL in any 24-hour period.
Timing in relation to meals (if applicable) May be taken with or without food.
Preparation requirements (if applicable) None required, but the solution must be measured using a calibrated dosing device to ensure volume accuracy.
Age-group administration rules Not approved for use in children under 6 years of age. Reduced dose volumes are specified for children 6 to 12 years.
Missed-dose rules If a dose is missed, take it when remembered unless it is near the time for the next scheduled dose; do not take two doses at the same time.
Special procedural conditions Use is strictly limited to a short-term duration for the management of acute symptoms.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral (Liquid Solution).
Frequency pattern Scheduled intervals of every 4 to 6 hours, used on an as-needed basis for acute symptoms.
Guideline basis Compound drug monograph.
Use-context constraints Usage is constrained to short-term application and must not involve co-administration with other Diphenhydramine-containing products.

Resulting Procedural Structure

Standard step sequence:

  • Measure the appropriate dose volume (e.g., 10 mL for adults) using a calibrated measuring tool.
  • Swallow the entire measured volume of the oral solution.
  • Observe the minimum 4-hour interval before taking the next dose.

Connection to the overall use protocol: This procedural structure defines the standardized use by establishing the precise volume, the required time interval between doses, and the maximum volume allowed over a 24-hour period. These requirements ensure that the administration method adheres to the established parameters for the product.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amydramine

This overview describes the research landscape for combination products like Amydramine, detailing the types of studies that have been conducted and the questions they addressed, without offering personal advice or specific treatment guidance.


Evidence for Use in Multi-Symptom Cold Relief

Research on multi-component preparations has been applied in studies examining patient-reported experiences of the common cold, a condition characterized by fluctuating or episodic manifestations. These evaluations primarily involve short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize the data from multiple trials. Studies explored outcomes related to physical discomfort and changes in overall symptom intensity in populations experiencing acute cold episodes.

Findings describe patterns of association observed in the studies regarding the combination's evaluation alongside global measures of illness severity. However, when research examined individual symptoms, such as sneezing and runny nose, measured changes were mixed across different studies. The evidence so far indicates that outcomes are typically observed over defined time intervals of a few days.

Evidence for Use in Acute Cough and Airway Secretion Management

Research has specifically explored whether cough symptoms could be addressed, as cough is often a key feature of conditions involving periods of heightened symptoms. This evidence base includes clinical studies, and research examined cough reflex sensitivity in laboratory-based settings under controlled conditions. The studies explored outcomes linked to inflammatory or irritative states, monitoring patient-reported outcomes describing perceived discomfort related to cough frequency and severity.

Research describes that the antitussive component was observed in some studies where changes in the cough reflex sensitivity threshold were measured. In real-world clinical settings, studies monitored outcomes related to physical discomfort, though findings were mixed during comparisons with inactive controls.

Known Evidence Gaps and Areas of Uncertainty

Research highlights that the follow-up durations were limited, typically lasting only as long as the acute illness. There is also limited information for long-term outcomes. One key area is that the comparative evidence is lacking for the full four-component preparation against other reference treatments, as much of the regulatory history is based on historical use and data from two- or three-component trials.

Key Studies & References Diphenhydramine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Amydramine (FAQ)

Q: How quickly does Amydramine start to work?

A: Official documents describing the active ingredient, Diphenhydramine, indicate it typically has a rapid onset of action. This means the effects are generally observed shortly after taking the oral solution.

Q: How long do the effects of Amydramine typically last?

A: The official administration guidelines recommend a dosing frequency of every 4 to 6 hours. This established time window reflects the expected duration of the medicine’s primary therapeutic effects.

Q: What is the difference between Amydramine and Benadryl (or similar drug class)?

A: Amydramine is described in official product information as a compound product containing four distinct active ingredients, including the antihistamine Diphenhydramine. In contrast, many comparable over-the-counter products are single-agent medicines.

Q: Does Amydramine affect the central nervous system?

A: Yes, regulatory documents state that the active ingredient Diphenhydramine is distributed widely throughout the body, including the central nervous system (CNS). This action is associated with CNS depression, which is why effects like sedation and drowsiness can occur.

Q: Is Amydramine available over the counter?

A: Products containing the active ingredients found in Amydramine are often regulated for Over-the-Counter (OTC) use for the temporary relief of symptoms. This classification means the medicine can be obtained without a prescription.

Q: What is the official safety classification for Amydramine during pregnancy?

A: Official labeling for the active ingredient notes that there are no adequate and well-controlled studies conducted in pregnant women. For this reason, use during pregnancy is generally restricted to situations where the need for the medicine is clearly established.

Q: What is considered an 'overdose' of Amydramine?

A: Regulatory documents describe overdosage reactions that can involve either central nervous system depression or stimulation. Potential reactions may include hallucinations, convulsions, and serious heart problems. The maximum recommended dose should not be exceeded, according to official administration rules.

Q: What should I do if I miss a scheduled dose of Amydramine?

A: Official administration guidelines state that if a dose is missed, it should be taken when remembered, unless it is close to the time for the next scheduled dose. Official administration guidelines indicate that a double dose should not be taken to compensate for the one that was missed.

Q: Does Amydramine have any effect on blood pressure?

A: Official adverse reaction reports list potential effects on the cardiovascular system. These include the possibility of low blood pressure (hypotension), as well as changes in heart rate such as palpitations or tachycardia. Caution is advised for patients with pre-existing high blood pressure (hypertension).

Q: Why is Amydramine sometimes mentioned for motion sickness?

A: The primary active ingredient, Diphenhydramine, is officially approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of motion sickness in certain formulations. The antihistaminic properties of the compound are responsible for this particular effect.

Q: Are there any specific foods or drinks to avoid while using Amydramine?

A: Official drug documents include a warning against consuming alcohol due to the risk of increased sedation and impairment. Beyond alcohol, there are typically no specific regulatory warnings that prohibit the use of ordinary foods or non-alcoholic beverages while using this medicine.

Q: Why do some people use Amydramine for sleep, even if it's not a sleep aid?

A: Diphenhydramine is an active ingredient found in many non-prescription products officially regulated as nighttime sleep aids. This is due to the compound’s most common side effect being central nervous system depression, which causes sedation and drowsiness.

Q: What organs in the body are primarily responsible for clearing Amydramine?

A: According to official labeling on the clinical pharmacology, the active ingredient Diphenhydramine is primarily cleared from the body through metabolism in the liver. A portion of the drug is also excreted unchanged via the kidneys in the urine.

Q: Is Amydramine related to or derived from any natural substances?

A: The active components in Amydramine are generally synthetic chemical entities. For instance, the main active ingredient, Diphenhydramine Hydrochloride, is classified chemically as an ethanolamine derivative.

Q: What does the research say about long-term use of Amydramine?

A: Official regulatory documents, such as those published by the FDA, note that long-term studies to determine the potential for chronic effects, including carcinogenicity or mutagenicity, have not been conducted for the active ingredient. Usage is generally limited to short-term symptom relief.

Q: Is it possible to be allergic to Amydramine?

A: Yes, official labeling states that the medicine is contraindicated in people with known hypersensitivity. This includes a severe allergic reaction to Diphenhydramine Hydrochloride or other similar antihistamine compounds, which means its use is not recommended in these cases.

Q: Does Amydramine interact with common herbal supplements like St. John's Wort?

A: Official regulatory information indicates that the safety of combining this medicine with specific herbal remedies and supplements has not been thoroughly evaluated. There is generally not enough safety data to confirm that all such combinations are safe.

Q: How long must I wait to take Amydramine after taking another similar medicine?

A: Regulatory warnings include advice against combining this medicine with any other product that also contains Diphenhydramine. Additionally, a period of at least 14 days must pass after discontinuing therapy with Monoamine Oxidase Inhibitors (MAOIs) before using Amydramine.

Q: Are there different strengths or forms of Amydramine available?

A: While the current formulation is an oral solution, the active ingredient Diphenhydramine is available in multiple forms, including tablets and capsules. It is also found both as a single ingredient and in various combination products across different markets.

Q: Can Amydramine cause temporary memory issues?

A: Official adverse reaction reports list potential nervous system disorders. These include symptoms such as confusion, dizziness, and disturbed coordination.

Q: What research evidence exists for using Amydramine in different age groups?

A: Official safety information contains dedicated sections for both pediatric and geriatric use, detailing age-related risks. For example, specific warnings address the potential for paradoxical excitation (restlessness) in children and the increased risk of confusion in older adults.

Q: What is the chemical class that Amydramine belongs to?

A: The active ingredient Diphenhydramine Hydrochloride is officially classified chemically as an ethanolamine derivative. It is classified pharmacologically as a first-generation histamine H1 receptor antagonist.

Q: What happens if Amydramine is taken past its expiration date?

A: The U.S. Food and Drug Administration (FDA) indicates that any medicine should not be used past its printed expiration date. This is because there is no guarantee that the medicine will remain safe, fully effective, or maintain its intended potency after that time.

Q: Can Amydramine cause stomach upset or nausea?

A: Official adverse reaction reports list potential gastrointestinal (GI) side effects. These can include nausea, vomiting, diarrhea, constipation, and general epigastric distress.

Q: Is Amydramine safe for people with high blood pressure?

A: Official regulatory documents advise that this medicine should be used with caution in patients who have pre-existing high blood pressure (hypertension) or cardiovascular disease. This caution is noted due to potential effects on the heart rate and blood pressure.

How should Amydramine be stored and disposed of?

The storage and disposal of Amydramine (oral solution) must strictly follow the requirements defined in governmental regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Do not freeze the oral solution.
Container Keep in the original container and ensure it is tightly closed to protect integrity.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Amydramine should be discarded through an available drug take-back program as the preferred method. If a take-back program is unavailable, mix the liquid with an unappealing substance (such as dirt or cat litter), place it in a sealed bag or container, and dispose of it in the household trash. Do not dispose of the medication by flushing it down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amydramine found in:

A-Z Index: